Eisai, Astellas Launch New Initiatives For Neglected Tropical Diseases For Corporate Responsibility And To Plant Seeds For New Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharmas’ interest in market expansion is leading companies to increase activity in global medicine access issues.
You may also be interested in...
Eisai Expands Relationship With Johns Hopkins For Neurological Disorders, Partnering Through "Open Innovation"
TOKYO - Eisai Co. Ltd. will build on its existing relationship with the Johns Hopkins Brain Science Institute, announcing a drug discovery collaboration for neurology Oct. 17
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.